BLINKLAB LIMITED (BB1)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BB1

BB1 - BLINKLAB LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: December
GICS Industry Group : NONE
Debt/EBITDA: -0.05
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.673

13 Aug
2026

-0.032

OPEN

$0.70

-4.54%

HIGH

$0.70

223,177

LOW

$0.67

TARGET
$1.76 161.5% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AVE . AYA . BRN . CAT . CBL . CGS . CMP . COH . CSX . CTE . CU6 . CVB . CYC . EBR . EIQ . EMV . EYE . FPH . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
BB1: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 5.5 - 4.6 xxx
DPS (cps) xxx 0.0 N/A xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 2023202420252026
EPS Basic xxxxxxxxx-5.5
DPS All xxxxxxxxx0.0
Sales/Revenue xxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxx12.8
Net Operating Cash Flow xxxxxxxxx-6.2 M
Net Profit Margin xxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 2023202420252026
Return on Capital Employed xxxxxxxxx-50.72 %
Return on Invested Capital xxxxxxxxx-50.07 %
Return on Assets xxxxxxxxx-47.77 %
Return on Equity xxxxxxxxx-50.72 %
Return on Total Capital xxxxxxxxx-58.13 %
Free Cash Flow ex dividends xxxxxxxxx-6.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 2023202420252026
Short-Term Debt xxxxxxxxx0 M
Long Term Debt xxxxxxxxx0 M
Total Debt xxxxxxxxx0 M
Goodwill - Gross xxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxx18 M
Price To Book Value xxxxxxxxx4.86

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 2023202420252026
Capex xxxxxxxxx1.3 M
Capex % of Sales xxxxxxxxx-
Cost of Goods Sold xxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxx8 M
Research & Development xxxxxxxxx5 M
Investments - Total xxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

12/08/2026

1

Speculative Buy

$1.76

161.52%

Morgans views BlinkLab's European ADHD study as an encouraging step towards broadening its smartphone-based diagnostic platform beyond autism.

The study achieved 82% sensitivity and 83% specificity across 208 children, supporting further development of the AI-driven Dx2 diagnostic model.

A US pilot study is planned before a pivotal FDA study, with the broker seeing ADHD as a potentially larger commercial opportunity than paediatric autism.

BlinkLab reported an FY26 net loss of -$7.2m and finished with $17.9m cash, providing funding into calendar 2027 as autism study results approach.

Morgans retains its Speculative Buy rating and $1.76 target, comprising $1.06 for autism and $0.70 for ADHD.

FORECAST
Morgans forecasts a full year FY27 EPS of minus -4.60 cents.
Morgans forecasts a full year FY28 EPS of minus -4.90 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

BB1 STOCK CHART

FNArena News on BB1

1
Dr Boreham’s Crucible: Blinklab

May 20 2024 - Small Caps

Latest Medical Equipment & Devices News

1
Rudi Interviewed: Bear Market Be Gone

Aug 13 2026 - Rudi's View
2
Are Headwinds Building For ResMed In FY27?

Jul 14 2026 - Australia
3
A Technical Breakout For ResMed

Jul 07 2026 - Technicals
4
Awaiting Catapult Sports’ Fundamental Re-Rating

Jun 15 2026 - Small Caps
5
Treasure Chest: Pro Medicus

Jun 04 2026 - Treasure Chest
6
Cochlear’s Shock Downgrade Raises Concerns

Apr 23 2026 - Australia
7
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
8
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
9
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
10
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals